Doubts Raised About Use of Products Containing Oxybenzone

This article originally appeared here.
Share this content:
Doubts Raised About Use of Products Containing Oxybenzone
Doubts Raised About Use of Products Containing Oxybenzone

TUESDAY, Nov. 21, 2017 (HealthDay News) -- Use of oxybenzone (Benzophenone-3) in sunscreen and personal care products should be minimized due to its dermatological and environmental toxicity, according to a review published online Oct. 31 in the Journal of Cosmetic Dermatology.

Joseph C. DiNardo, from Vesuvius, and Craig A. Downs, Ph.D., from Haereticus Environmental Laboratory, both in Virginia, described the toxicological impact of oxybenzone.

The researchers note that about 97 percent of people tested have oxybenzone present in their urine and that various concentrations are present in waterways and fish worldwide. Oxybenzone can react with chlorine, producing hazardous by-products; these can concentrate in swimming pools and wastewater treatment plants. The closed loop of ingesting fish contaminated with oxybenzone and/or washing the ingredient off bodies and having it return to drinking water may result in an increase in adverse reactions. Oxybenzone has been reported to produce contact and photocontact allergy reactions and to be a possible endocrine disrupter and may be linked to Hirschsprung's disease. Oxybenzone produces toxic reactions environmentally, including reef bleaching in coral and mortality in fish.

"With the rise in skin cancer rates and the availability of more effective sunscreen actives such as micronized zinc oxide and titanium dioxide, serious doubts about the relative prevention benefit of personal care products containing oxybenzone must be raised and compared with the potential negative health and environmental effects caused by the accumulation of this and other chemicals in the ecosystem," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »